EUCTR2009-013410-26-FR进行中（未招募）1 期
An open-label, randomized, multicenter, phase II, comparative, exploratory study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to Positon Emission Tomography (PET) value modification in patients with early stage HER2 positive breast cancer - AVATAXHER
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ROCHE SAS
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •General inclusion criteria:
- •2. Age = 18 years
- •3. Patient must have signed a written informed consent form prior to any study specific screening procedures
- •4. Patients able to undergo a pre-treatment PET and a second course PET
- •5. Affiliated to the ”Sécurité Sociale” or beneficiary to such a regimen
- •Disease specific inclusion criteria:
- •1. Patient with invasive, T2 or T3 and histologically confirmed breast cancer, who is
- •scheduled to receive neoadjuvant therapy with the objective of conservative surgery
- •(see Appendix 2)
- •2. Nx ou N0 or N1 (see Appendix 2)
- •3. HER2 positive (needle core biopsy only) assessed by ICH [HER2 +++ or HER2 ++
- •(and FISH or CISH + or SISH+)] or FISH + or CISH + or SISH +, on the basis of
- •ASCO 2007 criteria (see Appendix 3)
- •4. Known hormone receptors status.
- •5. Performance status (ECOG Scale, see Appendix 4): 0, 1 or 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Cancer related Exclusion Criteria:
- •1. Partially or totally lobular carcinoma
- •2. Inflammatory breast cancer
- •3. Bifocal and/or bilateral tumor
- •4. Metastases
- •5. Previous treatment with chemotherapy, radiation therapy or hormonal therapy for
- •breast tumor
- •6. Previous history of cancer (other than curatively treated basal and squamous cell
- •carcinoma of the skin and/or in-situ carcinoma of the cervix) relapsing within the 5
- •years before study entry or in situ contralateral breast carcinoma.
- •Haematological, biochemical and organ function:
- •1. Absolute neutrophil count (ANC) < 1.2 x 109/L
- •2. Platelet count <100 x 109/L
- •3. Haemoglobin < 9.00 g/dL
- •4. Impaired liver function: Serum (total) bilirubin: > 1.5 x ULN (except if Gilbert
- •hemolysis); AST or ALT: > 2.5 x ULN
- •5. Inadequate kidney function: serum creatinine > 1.25 ULN or creatinine clearance < 50 mL/min according to the Cockroft and Gault formula
- •6. Urine dipstick for proteinuria = 2+. Patients discovered to have = 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must
- •demonstrate = 1 g of protein in 24 hours
- •7. Patients not receiving anticoagulant medication and having an International
- •Normalized Ratio (INR) >1.5 or an activated Partial Thromboplastin Time (aPTT) or
- •PTT >1.5 x ULN within 7 days prior to first study treatment (4).
- •Note: Patients receiving full dose oral or parenteral anticoagulants may be included in the study as long as anticoagulant dosing has been stable for at least two weeks prior to study entry and the appropriate coagulation monitoring tests are within local therapeutic limits (4).
- •Other Study Drug Related Exclusion Criteria
- •1. Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic >100 mmHg), with or without anti-hypertensive medication. Patients with high initial blood pressure are eligible if entry criteria are met after initiation or adjustment of antihypertensive medication.
- •2. History of thrombotic disorders within the last 6 months prior to enrolment (i.e.
- •cerebrovascular accident, transient ischaemic attacks).
- •3. History of abdominal fistula, tracheo-oesophageal fistula or any grade 4 non gastrointestinal
- •fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment.
- •4. History or evidence of inherited bleeding diathesis or coagulopathy.
- •5. Non-healing wound, active peptic ulcer or bone fracture.
- •6. Major surgery (including open biopsy), significant traumatic injury within 28 days
- •prior to enrollment or anticipation of the need for major surgery during study
- •7. Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to
- •the first bevacizumab infusion (4).
- •8. Current or recent use of any non-steroidal anti inflammatory agent (aspirin > 325
- •mg/day), or anti aggregation agents (dypiridamole, ticlopidine, clopidogrel > 75
- •mg/day), within 10 days before the first administration of bevacizumab (4).
- •General Exclusion Criteria
- •1. Severe resting dyspnea due to complications or oxygen dependency
- •2. Clinically significant (i.e. active) cardiovascular disease, i.e. myocardial infarction
- •within the last 6 months before inclusion, unstable angina, congestive heart failure
- •NYHA Class = II (see Appendix 5), serious cardiac arrhythmia requiring medication
- •during the study which might interfere with regularity of the study treatment or not
- •controlled by medication.
- •3. LVEF = 50% by local definition using MUGA or echo cardiogram
- •4. Patient suffering fro
研究者
相似试验
进行中（未招募）
1 期
An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after first-line oxaliplatin - containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancerMedDRA version: 17.0Level: HLTClassification code 10008442Term: ChemotherapiesSystem Organ Class: 100000004865MedDRA version: 17.0Level: LLTClassification code 10069759Term: KRAS mutationSystem Organ Class: 100000004867colorectal cancerEUCTR2014-002417-36-ITFondazione IRCCS Istituto Nazionale dei Tumori82
进行中（未招募）
1 期
A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with paclitaxel and carboplatin against anaplastic thyroid carcinoma - N/AAnaplastic Thyroid CarcinomaMedDRA version: 9.1 Level: PT Classification code 10002240 Term: Anaplastic thyroid cancerEUCTR2007-002846-38-GBOXiGENE, Inc.180
招募中
2 期
An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS - PURO - AB 23/09bladder cancerC67Malignant neoplasm of bladderDRKS00003516GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH124
进行中（未招募）
不适用
An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS - PUROEUCTR2009-015119-42-DEGMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
招募中
2 期
A trial of sodium-copper-chlorophyllin given along with treatment of physicianâ??s choice versus treatment of physicianâ??s choice in asymptomatic or mildly symptomatic patients with Covid-19CTRI/2021/02/030986IDRS Labs Private Limited